ARKG vs IHI

Key Takeaways

• ARKG is an actively managed thematic ETF targeting the genomics revolution across healthcare and related sectors, while IHI is a passively managed fund tracking a medical equipment index.
• ARK Genomic Revolution ETF (ARKG) holds 30-40 concentrated positions in innovative genomics and biotech companies, whereas iShares U.S. Medical Devices ETF (IHI) maintains approximately 46 holdings focused exclusively on U.S. medical device manufacturers and distributors.
• Expense ratios differ materially, with ARKG at 0.75% compared to IHI at 0.37%, reflecting the active versus passive structures.
• ARKG provides exposure to higher-risk, higher-potential growth themes such as gene editing and precision medicine, while IHI offers more stable exposure to established medical device leaders.
• Both ETFs target healthcare innovation but diverge in risk profile, with ARKG exhibiting greater volatility due to its thematic concentration and smaller-cap tilt versus IHI's large-cap medical equipment focus.
• Structural differences position ARKG for investors seeking disruptive genomics exposure and IHI for those preferring established medical technology stability within the broader healthcare sector.

Introduction

ARKG and IHI represent distinct approaches to healthcare sector exposure, with one emphasizing active thematic innovation in genomics and the other providing passive access to medical devices. These ETFs do not compete directly but offer investors alternative strategies for participating in healthcare advancements. ARKG targets companies advancing genomic technologies across multiple sectors, while IHI focuses on established U.S. medical equipment firms. In the current environment of ongoing innovation in biotechnology and steady demand for medical technologies, comparing these vehicles helps investors align portfolios with specific risk tolerances and thematic preferences.

ARK Genomic Revolution ETF (ARKG) Overview

ARK Genomic Revolution ETF (ARKG) is an actively managed exchange-traded fund launched in 2014 that seeks long-term capital growth by investing primarily in equity securities of companies relevant to the genomics revolution. The fund typically holds 30-40 positions, with significant concentration in a handful of holdings. As of late August 2026, top positions included 10x Genomics Inc (TXG), Twist Bioscience Corp (TWST), Tempus AI Inc (TEM), CRISPR Therapeutics AG (CRSP), and Personalis Inc (PSNL). The portfolio emphasizes healthcare, particularly biotechnology and life sciences tools, with some allocation to information technology. ARKG carries an expense ratio of 0.75% and features active stock selection by ARK Investment Management, focusing on innovative firms in gene therapy, bioinformatics, and molecular medicine. The strategy is non-diversified and maintains flexibility to invest across market capitalizations and geographies where genomics themes apply.

iShares U.S. Medical Devices ETF (IHI) Overview

iShares U.S. Medical Devices ETF (IHI) is a passively managed fund launched in 2006 that seeks to track the performance of the Dow Jones U.S. Select Medical Equipment Index. The ETF holds approximately 46 securities, with a focus on U.S. companies involved in manufacturing and distributing medical devices such as imaging equipment, prosthetics, and surgical tools. As of August 2026, top holdings included Abbott Laboratories (ABT), Intuitive Surgical Inc (ISRG), Stryker Corp (SYK), Becton Dickinson and Co (BDX), and Dexcom Inc (DXCM). The portfolio allocates nearly 100% to the health care equipment sector. IHI features an expense ratio of 0.37% and employs a representative sampling indexing approach. The fund offers quarterly distributions and maintains high liquidity through its structure as an iShares product from BlackRock.

Industry and Thematic Backdrop

The healthcare sector continues to benefit from structural tailwinds including aging populations, technological advancements in diagnostics and treatment, and sustained investment in medical innovation. Genomics and precision medicine represent high-growth sub-themes driven by breakthroughs in gene editing and data analytics, while medical devices benefit from procedural volume recovery and adoption of minimally invasive technologies. Regulatory developments around healthcare reimbursement and innovation incentives influence both areas, alongside macroeconomic factors such as interest rate environments affecting capital-intensive biotech firms. Sector risks include clinical trial outcomes, competitive pressures, and potential policy shifts impacting device pricing and adoption. Capital flows into healthcare innovation remain robust across recent market cycles, supporting both thematic genomics exposure and established device manufacturers.

Performance and Positioning Comparison

In recent market cycles, ARKG has demonstrated higher volatility consistent with its concentrated active strategy and emphasis on smaller innovative companies, leading to more pronounced movements during shifts in growth sentiment or biotech funding conditions. IHI has exhibited relatively steadier behavior tied to large-cap medical device earnings and procedural demand trends. Relative positioning highlights ARKG's sensitivity to genomics-specific catalysts such as clinical advancements, while IHI responds more to broader healthcare utilization and capital equipment spending. During periods of sector rotation favoring established technologies, IHI's diversified large-cap profile has provided more defensive characteristics compared to ARKG's thematic focus. Both ETFs reflect healthcare's defensive qualities, yet their differing construction leads to distinct responses to interest rate expectations and innovation-driven market rotations.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening.

Tickeron AI Verdict

Based on structural strength, cost efficiency, diversification profile, and sector momentum, Tickeron’s AI would currently assign a higher probability of favorable positioning to IHI. Its lower expense ratio, passive indexing methodology, and exposure to established large-cap medical device companies provide a more consistent risk-adjusted profile within the healthcare sector compared to ARKG’s active thematic approach and higher costs. ARKG may appeal in environments with strong genomics momentum, but IHI’s characteristics align more closely with durable efficiency and lower volatility in the prevailing market environment.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations